Skip to main content

FOR US HEALTHCARE PROFESSIONALS ONLY

TYVASO and TYVASO DPI are approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

THE ARCHWAYS PROGRAM

Support while you begin treatment with TYVASO

Managing Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) and getting started on treatment with TYVASO (inhaled treprostinil) can leave you with questions. The United Therapeutics’ Archways program is here to help.

The United Therapeutics’ Archways program is a virtual, educational support program that offers helpful disease information and resources for treatment. Archways is available at no cost to patients and caregivers as you begin your treatment journey with TYVASO.

Connect one-on-one with an Archways Virtual Patient Educator to learn more about your condition and what to expect with your treatment.

To get started, follow one of these three simple steps:

 

United Therapeutics and the Archways program do not provide medical advice. You are advised to consult with your healthcare provider with any specific questions or concerns about your treatment.

NOW APPROVED—TYVASO DPI FITS IN THE PALM OF YOUR HAND

Ask your healthcare provider about the
Dry Powder Inhaler (DPI) option now approved for TYVASO®.

bubbles pattern
hand holding dpi devicebubbles pattern

See how simple TYVASO DPI is to use.

bubbles pattern